Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FARS2 antisense RNA 1 (FARS2-AS1) is a long non-coding antisense transcript overlapping, or located adjacent to, the FARS2 gene locus. As an antisense RNA, its potential function is to regulate the transcription or stability of the FARS2 mRNA, which encodes mitochondrial phenylalanyl-tRNA synthetase—a key enzyme in mitochondrial protein translation. Like other lncRNAs and antisense RNAs, FARS2-AS1 may act in cis (at its own locus) or in trans (at distant loci) to influence gene expression through diverse mechanisms such as chromatin remodeling, transcriptional interference, or RNA-RNA interactions. However, no detailed characterization, biological function, or disease association has been specifically reported for FARS2-AS1 itself in recent scientific literature or genetic databases. In summary, FARS2-AS1 is best classified as a long non-coding antisense RNA with poorly defined function and no evidence as a current or imminent therapeutic target.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FARS2 antisense RNA 1 (FARS2-AS1).